<SEC-DOCUMENT>0001415889-24-009394.txt : 20240329
<SEC-HEADER>0001415889-24-009394.hdr.sgml : 20240329
<ACCEPTANCE-DATETIME>20240329103909
ACCESSION NUMBER:		0001415889-24-009394
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240328
FILED AS OF DATE:		20240329
DATE AS OF CHANGE:		20240329

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Haddadin Yezan Munther
		CENTRAL INDEX KEY:			0001718004
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37759
		FILM NUMBER:		24802495

	MAIL ADDRESS:	
		STREET 1:		ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA
		STREET 2:		4TH FLOOR, PO BOX 142904
		CITY:			AMMAN
		STATE:			M2
		ZIP:			11844

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Outlook Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001649989
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				383982704
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	BUSINESS ADDRESS:	
		STREET 1:		485 ROUTE 1 SOUTH
		STREET 2:		BUILDING F, SUITE 320
		CITY:			ISELIN
		STATE:			NJ
		ZIP:			08830
		BUSINESS PHONE:		6096193990

	MAIL ADDRESS:	
		STREET 1:		485 ROUTE 1 SOUTH
		STREET 2:		BUILDING F, SUITE 320
		CITY:			ISELIN
		STATE:			NJ
		ZIP:			08830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Oncobiologics, Inc.
		DATE OF NAME CHANGE:	20150804
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4-03292024_020304.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-03-28</periodOfReport>

    <issuer>
        <issuerCik>0001649989</issuerCik>
        <issuerName>Outlook Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>OTLK</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001718004</rptOwnerCik>
            <rptOwnerName>Haddadin Yezan Munther</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O OUTLOOK THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>485 ROUTE 1 SOUTH, BUILDING F, SUITE 320</rptOwnerStreet2>
            <rptOwnerCity>ISELIN</rptOwnerCity>
            <rptOwnerState>NJ</rptOwnerState>
            <rptOwnerZipCode>08830</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <transactionDate>
                <value>2024-03-28</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>P</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>1881.7112</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>11.82</value>
                    <footnoteId id="F1"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>5048.7112</value>
                    <footnoteId id="F2"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $11.78 to $11.8249 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.</footnote>
        <footnote id="F2">Reflects the Issuer's 1-for-20 reverse stock split effected on March 13, 2024.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Lawrence Kenyon, Attorney-in-Fact</signatureName>
        <signatureDate>2024-03-29</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
